Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Total Current Liabilities (2016 - 2025)

Enanta Pharmaceuticals filings provide 14 years of Total Current Liabilities readings, the most recent being $44.7 million for Q4 2025.

  • On a quarterly basis, Total Current Liabilities fell 8.81% to $44.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $44.7 million, a 8.81% decrease, with the full-year FY2025 number at $48.6 million, down 15.61% from a year prior.
  • Total Current Liabilities hit $44.7 million in Q4 2025 for Enanta Pharmaceuticals, down from $48.6 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $68.2 million in Q2 2023 to a low of $23.0 million in Q4 2022.
  • Median Total Current Liabilities over the past 5 years was $44.6 million (2025), compared with a mean of $43.2 million.
  • Biggest five-year swings in Total Current Liabilities: tumbled 39.3% in 2022 and later surged 196.02% in 2023.
  • Enanta Pharmaceuticals' Total Current Liabilities stood at $37.9 million in 2021, then tumbled by 39.3% to $23.0 million in 2022, then soared by 171.32% to $62.4 million in 2023, then fell by 21.4% to $49.0 million in 2024, then fell by 8.81% to $44.7 million in 2025.
  • The last three reported values for Total Current Liabilities were $44.7 million (Q4 2025), $48.6 million (Q3 2025), and $44.5 million (Q2 2025) per Business Quant data.